# Immunogenicity and Safety of an Intramuscular A/H5N1 Inactivated, Split Virion Pandemic Influenza Vaccine in Adults

> **NCT00545701** · PHASE2 · COMPLETED · sponsor: **Sanofi Pasteur, a Sanofi Company** · enrollment: 100 (actual)

## Conditions studied

- Influenza
- Orthomyxoviridae Infections

## Interventions

- **BIOLOGICAL:** A/H5N1 inactivated, split-virion influenza virus

## Key facts

- **NCT ID:** NCT00545701
- **Lead sponsor:** Sanofi Pasteur, a Sanofi Company
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2007-10
- **Primary completion:** 2008-06
- **Final completion:** 2008-09
- **Target enrollment:** 100 (ACTUAL)
- **Last updated:** 2014-01-14


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00545701

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00545701, "Immunogenicity and Safety of an Intramuscular A/H5N1 Inactivated, Split Virion Pandemic Influenza Vaccine in Adults". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT00545701. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*